Skip to main content
Erschienen in: Tumor Biology 8/2014

01.08.2014 | Research Article

Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/β-catenin pathway in laryngeal cancer Hep-2 cells

verfasst von: Ning Yang, Lian Hui, Yan Wang, Huijun Yang, Xuejun Jiang

Erschienen in: Tumor Biology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

SOX2 is a high-mobility group box containing transcription factor essential for the maintenance of embryonic stem cells. Recent evidence indicates that SOX2 overexpression correlates with metastasis and poor prognosis in patients with laryngeal squamous cell cancer. To investigate how SOX2 contributes to this aggressive phenotype, we introduced the human SOX2 gene into a low SOX2-expressing human laryngeal cancer cell line Hep-2. Cell migration and invasion were determined by the Transwell assay with or without Matrigel coating. The epithelial-mesenchymal transition (EMT)-related markers were assayed by Western blot analysis or immunofluorescence. Our results showed that exogenous expression of SOX2 in Hep-2 cells substantially promoted their migratory and invasive capabilities in culture. Moreover, Hep-2 cells stably overexpressing SOX2 underwent EMT phenotype, as evidenced by mesenchymal morphology, decreased expression of epithelial marker (E-cadherin), and increased expression of mesenchymal markers (N-cadherin, vimentin, fibronectin, and α-smooth muscle actin). Strikingly, Western blot analysis and immunofluorescence also showed that overexpression of SOX2 resulted in substantial increase and nuclear accumulation of β-catenin in Hep-2 cells. However, small interfering RNA targeting β-catenin significantly attenuated the reduced expression of E-cadherin and increased cell migration and invasion abilities in SOX2-overexpressing cells, suggesting that SOX2-induced EMT process, migration, and invasion are dependent on β-catenin activation. Taken together, our findings underscore a novel role for SOX2 in laryngeal cancer migration and invasion.
Literatur
5.
Zurück zum Zitat Galera-Ruiz H, Rios-Moreno MJ, Gonzalez-Campora R, Galera-Davidson H. WNT pathway in laryngeal squamous cell carcinoma and nasopharyngeal carcinoma. Acta Otorhinolaryngol Ital Organo ufficiale della Societa italiana di Otorinolaringol Chir Cervicofac. 2012;32(2):122–3. Galera-Ruiz H, Rios-Moreno MJ, Gonzalez-Campora R, Galera-Davidson H. WNT pathway in laryngeal squamous cell carcinoma and nasopharyngeal carcinoma. Acta Otorhinolaryngol Ital Organo ufficiale della Societa italiana di Otorinolaringol Chir Cervicofac. 2012;32(2):122–3.
6.
10.
12.
Zurück zum Zitat Shah JP, Karnell LH, Hoffman HT, Ariyan S, Brown GS, Fee WE, et al. Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. 1997;123(5):475–83.PubMedCrossRef Shah JP, Karnell LH, Hoffman HT, Ariyan S, Brown GS, Fee WE, et al. Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. 1997;123(5):475–83.PubMedCrossRef
14.
Zurück zum Zitat Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev. 1997;7(3):338–44.PubMedCrossRef Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev. 1997;7(3):338–44.PubMedCrossRef
15.
Zurück zum Zitat Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells. 2009;27(1):40–8. doi:10.1634/stemcells.2008-0493.PubMedCrossRef Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells. 2009;27(1):40–8. doi:10.​1634/​stemcells.​2008-0493.PubMedCrossRef
19.
Zurück zum Zitat Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas. 2006;32(2):164–70. doi:10.1097/01.mpa.0000202947.80117.a0.PubMedCrossRef Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas. 2006;32(2):164–70. doi:10.​1097/​01.​mpa.​0000202947.​80117.​a0.PubMedCrossRef
21.
Zurück zum Zitat Xu XL, Xing BC, Han HB, Zhao W, Hu MH, Xu ZL, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis. 2010;31(2):167–74. doi:10.1093/carcin/bgp232.PubMedCrossRef Xu XL, Xing BC, Han HB, Zhao W, Hu MH, Xu ZL, et al. The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis. 2010;31(2):167–74. doi:10.​1093/​carcin/​bgp232.PubMedCrossRef
24.
Zurück zum Zitat Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart JM, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs. 2007;185(1–3):61–5. doi:10.1159/000101304.PubMedCrossRef Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart JM, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs. 2007;185(1–3):61–5. doi:10.​1159/​000101304.PubMedCrossRef
25.
Metadaten
Titel
Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/β-catenin pathway in laryngeal cancer Hep-2 cells
verfasst von
Ning Yang
Lian Hui
Yan Wang
Huijun Yang
Xuejun Jiang
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 8/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2045-3

Weitere Artikel der Ausgabe 8/2014

Tumor Biology 8/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.